Certolizumab Pegol for the Treatment of Moderate to Severe Plaque Psoriasis: 16-Week Results from a Phase 2/3 Japanese Study
mediaposted on 2021-02-17, 10:56 authored by Adis journals on behalf of, Yoshinori Umezawa, Shinya Sakurai, Naoki Hoshii, Hidemi Nakagawa
Article full text
The above summary slide represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online (see “read the peer-reviewed publication” opposite).
© The authors, CC-BY-NC 2021.